• Design enhancements allow for faster preparation of Floseal with same trusted safety and efficacy

  • Reinforces Baxter’s efforts to develop products that support operating room nurses and surgeons

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced that it has received U.S. Food and Drug Administration (FDA) approval for faster preparation of its leading hemostatic product, Floseal Hemostatic Matrix, at the 2019 Association of periOperative Registered Nurses (AORN) Global Surgical Conference and Expo. This next generation of Floseal has 20 percent fewer components and steps to prepare,[1] making it easier and faster for operating room (OR) nurses to get Floseal in the hands of surgeons to help stop bleeding during procedures. The new design will be on display at Baxter’s AORN booth #1624.

“We are focused on advancing the art of healing in the operating room with our innovative and dependable surgical products that address intraoperative bleeding,” said Wil Boren, president of Baxter’s Advanced Surgery business. “When creating the next generation of Floseal, we had OR nurses in mind. We listened to their feedback so that we could deliver on our promise of customer-inspired innovation.”

With 20 years of leadership in hemostasis and as a frequently chosen advanced hemostatic agent,[2] Floseal has been proven to perform quickly and consistently across a range of bleeds in surgical procedures.[3] A 13cm Malleable Applicator is included with every Floseal kit and allows surgeons to maneuver the product into the proper position.

“I’ve spent my entire career involved with surgery in various capacities, and I’ve seen firsthand the importance that speed and precision play when it comes to preventing bleeding complications for patients,” said Mary Anne Sanford, BSN, RN, CNOR and senior manager, Global Medical Affairs at Baxter. “The latest design enhancements to Floseal make it easier and faster to prepare, enhancing the ability of perioperative nurses to focus their efforts to coordinate and support the surgical team’s activities throughout a procedure.”

Floseal has been ranked by registered nurses in ORs across the U.S. as the flowable configuration of choice because of its simple and easy preparation.[4] In this latest design, the diluent ampoule has been replaced by pre-filling the existing mixing syringe so that Floseal can be prepared more quickly than the current configuration.

Both active and passive adjunctive hemostatic agents are available to help control bleeding in surgical procedures when ligature or conventional methods are ineffective or impractical. Baxter’s broad portfolio of hemostatic and sealing agents effectively work to stop bleeding in a variety of anatomies to help lower bleeding-related complications and to reduce overall costs. To learn more about Floseal and the rest of Baxter’s portfolio, please visit advancedsurgery.baxter.com.


[1] Floseal Hemostatic Matrix Instructions for Use. Hayward, CA: Baxter Healthcare Corporation.

[2] 2017 total unit sales (DRG data)

[3] D. Makhija, M. Rock, Y. Xiong, J. D. Epstein, M. R. Arnold, O. M. Lattouf & D. Calcaterra (2017) Cost-consequence analysis of different active flowable hemostatic matrices in cardiac surgical procedures, Journal of Medical Economics, 20:6, 565-573, DOI:10.1080/13696998.2017.1284079

[4] Data on file – Time Motion Study – Study Number: BXU528129